Nucleotide sugar transporter SLC35B4
Golgi apparatus
<i>SLC35B4</i>, an Inhibitor of Gluconeogenesis, Responds to Glucose Stimulation and Downregulates Hsp60 among Other Proteins in HepG2 Liver Cell Lines.
<i>SLC35B4</i>, solute receptor for UDP-<i>N</i>-acetylglucosamine and UDP-xylose, is associated with diabetes and predisposing conditions. This study investigated the localization of <i>SLC35B4</i> and compared the differential expression between a knockdown of <i>SLC35B4</i> and controls in HepG2. Responsiveness to glucose, expression, and localization were assayed using Western blot and immunostaining. Localization was confirmed using a proximity ligation assay. Two-dimensional (2D) gel electrophoresis and MALDI-TOF were used to identify differentially expressed proteins and pathway analysis was performed. <i>SLC35B4</i> was increased by 60% upon glucose stimulation and localized in Golgi apparatus and endoplasmic reticulum. Presence of <i>SLC35B4</i> in the Golgi apparatus suggests its involvement in the biosynthesis of glycoconjugate proteins. Four proteins were markedly under-expressed (Hsp60, HspA8, TUBA1A, and ENO1) and linked to the pathogenesis of diabetes or post-translationally modified by <i>O</i>-GlcNAc. Glucose levels activate <i>SLC35B4</i> expression. This triggers a downstream effect via Hsp60 and other proteins. We hypothesize that the downstream effect on the proteins is mediated via altering the glycosylation pattern inside liver cells. The downstream cascade ultimately alters the ability of cultured liver cells to inhibit endogenous glucose production, and this could play a role in the association of the above-listed genes with the pathogenesis of diabetes.